52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
CMA Issues Supplementary Objections On Probe Relating To Supply Of Hydrocortisone Tablets In UK
Allergan Reports Q4 Loss Per Share Of $0.97
AbbVie Expects 2020 Skyrizi Revenue Of ~$1.2 Bln And Rinvoq Revenue Of ~$500 Mln
Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.
Clonshaugh Business And Technology Park
Brenton L. Saunders
Chairman of the Board, President, Chief Executive Officer
Matthew M. Walsh
Chief Financial Officer, Executive Vice President
Karen Lee Ling
Chief Human Resource Officer, Executive Vice President
A. Robert D. Bailey
Executive Vice President, Chief Legal Officer and Corporate Secretary
William J. Meury
Executive Vice President, Chief Commercial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S. approval for AbbVie Inc's <ABBV.N> planned purchase of Allergan Plc <AGN.N>.
* ALLERGAN REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
AbbVie Inc <ABBV.N> on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc <AGN.N> to drive growth beyond 2023, when its cash cow Humira loses patent protection.
U.S. drugmaker AbbVie's <ABBV.N> $63 billion tie-up with Allergan <AGN.N> is getting help from Nestle <NESN.S> and AstraZeneca <AZN.L> buying up products the Irish-domiciled company is shedding to placate regulators.
Swiss food giant Nestle <NESN.S> on Monday bulked up its medical nutrition business by buying Allergan's <AGN.N> Zenpep, a product for people whose pancreases do not provide enough enzymes to properly digest fats, proteins and sugars.
Nestle on Monday said it is buying Allergan's Zenpep to expand in medical nutrition with a product for people who cannot digest food properly because their pancreas does not provide enough enzymes to break down fat, protein, and carbohydrates.
The European Commission said on Friday it had approved U.S. drugmaker AbbVie's <ABBV.N> planned $63 billion (48.24 billion pounds) acquisition of Botox-maker Allergan <AGN.N>, subject to conditions.
* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION
Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer's medication off the market.
The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc's drug for relieving migraine headaches after their onset.
The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc's drug for treating acute migraine in adults.
AbbVie Inc <ABBV.N> on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc <AGN.N>.
AbbVie Inc <ABBV.N> said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc <AGN.N>.
Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer's disease therapy Namenda, the drugmaker said, in a resolution to the litigation that was set to face trial on Monday.
Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer's disease therapy Namenda, resolving the litigation that was set to face trial this month.
The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc <ABBV.N> and botox maker Allergan Plc <AGN.N> on their $63 billion deal, the companies said on Friday.
About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...
Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.
Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.
Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.